Key result
Isradipine reduced supine diastolic blood pressure by 10 mm Hg in 88% of patients compared to 83% with propranolol, with no significant difference between groups.
Why the study?
Does isradipine reduce blood pressure compared to propranolol in hypertensive patients inadequately controlled on hydrochlorothiazide?
RCT (n=78)
Double-blind
parallel
Does isradipine reduce blood pressure compared to propranolol in hypertensive patients inadequately controlled on hydrochlorothiazide?
Isradipine is as effective as propranolol in reducing blood pressure when added to hydrochlorothiazide in patients with uncontrolled hypertension, though it is associated with a higher absolute frequency of adverse reactions.
Answers are grounded in this paper and cite their sources.
Supports isradipine as alternative to propranolol for add-on blood pressure control; confirms comparable efficacy in hydrochlorothiazide-treated hypertension.
A randomized, parallel, controlled study was conducted to evaluate the safety and efficacy of isradipine, 2.5 to 10 mg orally twice a day, compared with propranolol hydrochloride, 60 to 240 mg orally twice a day, in 78 hypertensives whose supine diastolic blood pressure was greater than 95 mm Hg while receiving 50 mg/d or more of hydrochlorothiazide. Isradipine or propranolol was titrated during a 10-week double-blind phase to achieve a supine diastolic blood pressure below 90 mm Hg while a fixed dose of hydrochlorothiazide was maintained. Supine diastolic blood pressure was reduced by 10 mm Hg in 88% of the isradipine/hydrochlorothiazide-treated and 83% of the propranolol/hydrochlorothiazide-treated groups and to less than 90 mm Hg in 55% of the isradipine/hydrochlorothiazide-treated and 69% of the propranolol/hydrochlorothiazide-treated patients. There was no significant difference in supine blood pressure reduction between either group, but there was a 3-to 4-beats per minute increase in supine heart rate in isradipine-treated patients and an expected 15- to 20-beats per minute decrease in heart rate in propranolol-treated patients. Five of 7 patients in the isradipine-treated group and 8 of 9 patients in the propranolol-treated group discontinued the therapy because of adverse reactions or treatment failure. Using Fisher's Exact Test, we found no significant difference in the relative frequency of individual adverse reactions between groups, although the absolute adverse reaction frequency was significantly higher with isradipine. This study demonstrates the effectiveness and safety of supplemental isradipine in the treatment of hypertension not controlled by hydrochlorothiazide alone.
No takes yet. Share an insight, caveat, or question.
L. Michael Prisant (1989) conducted an RCT in Hypertension (n=78). Isradipine vs. Propranolol hydrochloride, 60 to 240 mg orally twice a day was evaluated on Supine diastolic blood pressure reduced by 10 mm Hg. Isradipine reduced supine diastolic blood pressure by 10 mm Hg in 88% of patients compared to 83% with propranolol, with no significant difference between groups.
Synapse has enriched 10 related papers. Consider them for comparative context: